Form 4: Amylyx Pharmaceuticals Co-CEO Exercises Stock Options, Increasing Holdings

Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, exercised stock options on February 5, 2025, acquiring 36,310 shares of common stock.

Summary

• On February 5, 2025, Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals, exercised stock options to acquire 36,310 shares of common stock at a price of $1.57 per share.
• This transaction increased Klee's direct holdings to 3,201,243 shares of Amylyx Pharmaceuticals.
• The stock options were fully vested and exercisable on the transaction date.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine transaction. The Co-CEO exercising options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The Co-CEO's decision to exercise stock options could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential sentiment.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from the Co-CEO.

Key Dates

Keywords

Amylyx Pharmaceuticals, Justin B. Klee, stock options, Form 4, insider trading, beneficial ownership, AMLX